Literature DB >> 9430540

Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.

S Amano1, R Rohan, M Kuroki, M Tolentino, A P Adamis.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) is required for vascular development and for ischemia-related tumor, iris, and retinal neovascularization. The role of VEGF in inflammatory corneal neovascularization is unknown and was investigated in these studies.
METHODS: A rat model was used in which removal of the corneal and limbal epithelium resulted in circumferential neovascularization. Corneal VEGF mRNA levels were quantified with ribonuclease protection assays, and VEGF protein was studied in situ using immunohistochemical analysis. Controlled-release pellets containing anti-VEGF antibodies were implanted into the corneal stroma and were used to determine the requirement for VEGF in corneal neovascularization.
RESULTS: VEGF mRNA and protein were induced to high levels after corneal injury and were temporally and spatially correlated with inflammation and neovascularization. VEGF immunoreactivity was localized primarily to the inflammatory cells invading the wounded cornea. The specific inhibition of VEGF bioactivity with neutralizing antibodies potently suppressed corneal neovascularization.
CONCLUSIONS: These data are the first to demonstrate that VEGF may be required for inflammatory neovascularization of the rat cornea and to identify VEGF as a functional endogenous corneal angiogenic factor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9430540

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  78 in total

1.  Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats.

Authors:  N Saita; N Fujiwara; I Yano; K Soejima; K Kobayashi
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury.

Authors:  Y Moromizato; S Stechschulte; K Miyamoto; T Murata; A Tsujikawa; A M Joussen; A P Adamis
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.

Authors:  Iva Dekaris; Nikica Gabrić; Nataša Drača; Maja Pauk-Gulić; Neven Miličić
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

4.  Parstatin suppresses ocular neovascularization and inflammation.

Authors:  Hu Huang; Panagiotis Vasilakis; Xiufeng Zhong; Ji-Kui Shen; Katerina Geronatsiou; Helen Papadaki; Michael E Maragoudakis; Sotirios P Gartaganis; Stanley A Vinores; Nikos E Tsopanoglou
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

5.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

Review 6.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

7.  Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice.

Authors:  Weiyun Shi; Chunping Ming; Juncai Liu; Ting Wang; Hua Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-17       Impact factor: 3.117

8.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

9.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Authors:  Francesca Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W Dunn; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-05-21       Impact factor: 3.072

10.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.